Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biotron Limited (BITRF)
OTHER OTC:BITRF
Holding BITRF?
Track your performance easily
BITRF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range<$0.01 - $0.08
Previous Close$0.01
Volume30.00K
Average Volume (3M)65.00K
Market Cap
$12.81M
Enterprise Value$11.70M
Total Cash (Recent Filing)AU$1.74M
Total Debt (Recent Filing)AU$77.24K
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Feb 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares OutstandingN/A
10 Day Avg. Volume13,000
30 Day Avg. Volume65,000
Standard Deviation0.28
R-Squared0.03
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)1059.75
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Biotron Limited News
PremiumCompany Announcements
Biotron Limited’s BIT225 Trial Shows Mixed Results
PremiumCompany Announcements
Biotron Limited Embraces Corporate Governance Standards
PremiumCompany Announcements
Biotron Emphasizes Strong Corporate Governance
PremiumCompany Announcements
Biotron Limited Reports Annual Financial LossPremiumCompany Announcements
Biotron Limited Reports Promising Trial Results
PremiumCompany Announcements
Biotron Limited Applies for New ASX Quotation
PremiumCompany Announcements
Biotron’s BIT225 Shows Promise in HIV Treatment
PremiumCompany Announcements
Biotron Limited Unveils Investor WebinarOptions Prices
Currently, No data available
---
Ownership Overview
3.63%
Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
96.37% Public Companies and
Individual Investors
BITRF FAQ
What was Biotron Limited’s price range in the past 12 months?
Biotron Limited lowest stock price was <$0.01 and its highest was $0.08 in the past 12 months.
What is Biotron Limited’s market cap?
Currently, no data Available
When is Biotron Limited’s upcoming earnings report date?
Biotron Limited’s upcoming earnings report date is Feb 19, 2025 which is in 152 days.
How were Biotron Limited’s earnings last quarter?
Biotron Limited released its earnings results on Aug 29, 2024. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
Is Biotron Limited overvalued?
According to Wall Street analysts Biotron Limited’s price is currently Overvalued.
Does Biotron Limited pay dividends?
Biotron Limited does not currently pay dividends.
What is Biotron Limited’s EPS estimate?
Biotron Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biotron Limited have?
Biotron Limited has 902,309,270 shares outstanding.
What happened to Biotron Limited’s price movement after its last earnings report?
Biotron Limited reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biotron Limited?
Currently, no hedge funds are holding shares in BITRF
---
Biotron Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.00%
12-Months-Change
Fundamentals
Return on Equity
-231.33%
Trailing 12-Months
Asset Growth
-88.03%
Trailing 12-Months
Company Description
Biotron Limited
Biotron Ltd is a biotechnology company. The company is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia.
---
Technical Analysis
Northwest Biotherapeutics
―
Inovio Pharmaceuticals
―
Advaxis
―
ImmunoCellular Therapeutics
―
---